Skip to content

Novel therapies for secretory diarrhea

Novel therapies for secretory diarrhea - Novel therapies for SD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON39183
Enrollment
32
Registered
2013-04-16
Start date
2013-09-05
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ETEC infection Traveler's diarrhea

Interventions

Biopsies will be sampled from the rectum with a suction biopsy device.

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Must be 18-55 years old. Enrollment by informed written consent

Exclusion criteria

Exclusion criteria: Liver conditions; signs of portal hypertension Coagulation disorders or use of anti-coagulants (Chronic) constipation. (As this may indicate aberrant intestinal ion and fluid transport.)

Design outcomes

Secondary

MeasureTime frame
The effect of 6 GC-C signaling blockers on GC-C-independent intestinal solute transport, assessed by ICM (off-target effects).

Primary

MeasureTime frame
The effect of 6 GC-C signaling blockers and of 4 CFTR inhibitors on the pro-secretory response of human colon, assessed by ICM.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)